581 related articles for article (PubMed ID: 33710778)
1. Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer.
Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Urabe M; Mizukami H; Fujiwara H
Cancer Med; 2021 Apr; 10(8):2732-2739. PubMed ID: 33710778
[TBL] [Abstract][Full Text] [Related]
2. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
[TBL] [Abstract][Full Text] [Related]
3. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.
Iida-Norita R; Kawamura M; Suzuki Y; Hamada S; Masamune A; Furukawa T; Sato Y
Cancer Sci; 2019 Jul; 110(7):2296-2308. PubMed ID: 31074083
[TBL] [Abstract][Full Text] [Related]
4. Vasohibins/SVBP are tubulin carboxypeptidases (TCPs) that regulate neuron differentiation.
Aillaud C; Bosc C; Peris L; Bosson A; Heemeryck P; Van Dijk J; Le Friec J; Boulan B; Vossier F; Sanman LE; Syed S; Amara N; Couté Y; Lafanechère L; Denarier E; Delphin C; Pelletier L; Humbert S; Bogyo M; Andrieux A; Rogowski K; Moutin MJ
Science; 2017 Dec; 358(6369):1448-1453. PubMed ID: 29146868
[TBL] [Abstract][Full Text] [Related]
5. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
[TBL] [Abstract][Full Text] [Related]
6. Pathological Study on the Expression of Vasohibins in Peripheral Artery Disease.
Isoda R; Morita I; Ishida A; Mikami Y; Monobe Y; Sato Y; Moriya T
Tohoku J Exp Med; 2022 Sep; 258(2):121-128. PubMed ID: 35922907
[TBL] [Abstract][Full Text] [Related]
7. Tubulin carboxypeptidase activity of vasohibin-1 inhibits angiogenesis by interfering with endocytosis and trafficking of pro-angiogenic factor receptors.
Kobayashi M; Wakabayashi I; Suzuki Y; Fujiwara K; Nakayama M; Watabe T; Sato Y
Angiogenesis; 2021 Feb; 24(1):159-176. PubMed ID: 33052495
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
[TBL] [Abstract][Full Text] [Related]
9. In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.
Koyanagi T; Suzuki Y; Saga Y; Machida S; Takei Y; Fujiwara H; Suzuki M; Sato Y
Cancer Sci; 2013 Dec; 104(12):1705-10. PubMed ID: 24118388
[TBL] [Abstract][Full Text] [Related]
10. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
11. Depletion of Vasohibin 1 Speeds Contraction and Relaxation in Failing Human Cardiomyocytes.
Chen CY; Salomon AK; Caporizzo MA; Curry S; Kelly NA; Bedi K; Bogush AI; Krämer E; Schlossarek S; Janiak P; Moutin MJ; Carrier L; Margulies KB; Prosser BL
Circ Res; 2020 Jul; 127(2):e14-e27. PubMed ID: 32272864
[TBL] [Abstract][Full Text] [Related]
12. Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression.
Ge Q; Zhou J; Tu M; Xue X; Li Z; Lu Z; Wei J; Song G; Chen J; Guo F; Jiang K; Miao Y; Gao W
Oncol Rep; 2015 Sep; 34(3):1327-36. PubMed ID: 26177649
[TBL] [Abstract][Full Text] [Related]
13. VASH1-SVBP and VASH2-SVBP generate different detyrosination profiles on microtubules.
Ramirez-Rios S; Choi SR; Sanyal C; Blum TB; Bosc C; Krichen F; Denarier E; Soleilhac JM; Blot B; Janke C; Stoppin-Mellet V; Magiera MM; Arnal I; Steinmetz MO; Moutin MJ
J Cell Biol; 2023 Feb; 222(2):. PubMed ID: 36512346
[TBL] [Abstract][Full Text] [Related]
14. Role of the vasohibin family in the regulation of fetoplacental vascularization and syncytiotrophoblast formation.
Suenaga K; Kitahara S; Suzuki Y; Kobayashi M; Horie S; Sugawara J; Yaegashi N; Sato Y
PLoS One; 2014; 9(9):e104728. PubMed ID: 25184477
[TBL] [Abstract][Full Text] [Related]
15. Vasohibins encode tubulin detyrosinating activity.
Nieuwenhuis J; Adamopoulos A; Bleijerveld OB; Mazouzi A; Stickel E; Celie P; Altelaar M; Knipscheer P; Perrakis A; Blomen VA; Brummelkamp TR
Science; 2017 Dec; 358(6369):1453-1456. PubMed ID: 29146869
[TBL] [Abstract][Full Text] [Related]
16. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
17. High Vasohibin-2 expression correlated with autophagy in proliferative diabetic retinopathy.
Ding Y; Su N; Luan J; Xu J; Qiu S; Sun Z
Exp Eye Res; 2024 Mar; 240():109808. PubMed ID: 38278467
[TBL] [Abstract][Full Text] [Related]
18. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.
Koyanagi T; Suzuki Y; Komori K; Saga Y; Matsubara S; Fujiwara H; Sato Y
Cancer Sci; 2017 Mar; 108(3):512-519. PubMed ID: 28032401
[TBL] [Abstract][Full Text] [Related]
19. Plasma vasohibin-1 and vasohibin-2 are useful biomarkers in patients with esophageal squamous cell carcinoma.
Yamamoto M; Ozawa S; Ninomiya Y; Koyanagi K; Oguma J; Kazuno A; Hara H; Yatabe K; Kajiwara H; Nakamura N; Sato Y
Esophagus; 2020 Jul; 17(3):289-297. PubMed ID: 31980976
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary Divergence of Enzymatic Mechanisms for Tubulin Detyrosination.
van der Laan S; Lévêque MF; Marcellin G; Vezenkov L; Lannay Y; Dubra G; Bompard G; Ovejero S; Urbach S; Burgess A; Amblard M; Sterkers Y; Bastien P; Rogowski K
Cell Rep; 2019 Dec; 29(12):4159-4171.e6. PubMed ID: 31851940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
